Polychlorinated biphenyls (PCBs) and polybrominated diphenyl-ethers (PBDEs) are metabolized into hydroxylated metabolites (OH-PCBs/PBDEs), which can disrupt the thyroid hormone homeostasis. Binding of these metabolites to transport proteins such as transthyretin (TTR) is an important mechanism of their toxicity. Several methods to quantify the competitive thyroxine (T 4 ) displacement potency of pure metabolites exist. However, quantification of the potency of in vitro metabolized PCBs and PBDEs has drawbacks related to the coextraction of compounds disturbing the T 4 -TTR competitive binding assay. This study identifies and quantifies the major coextractants namely cholesterol, saturated and nonsaturated fatty acids (SFA and NSFA) at levels above 20 nmol per mg equivalent protein following various extraction methods. Their TTR binding potency was analyzed in a downscaled, nonradioactive fluorescence displacement assay. At concentration factors needed for TTR competitive binding, at least 10μM of these coextracts is present, whereas individual SFA and NSFA disturb the assay from 0.3μM. The effectiveness of the in vitro metabolism and extraction of the model compounds CB 77 and BDE 47 was chemically quantified with a newly developed chromatographic method analyzing silylated derivatives of the OH-metabolites and coextractants. A new method to selectively extract metabolites and limit coextraction of disturbing compounds to less than 5 nmol per mg equivalent protein is presented. It is now possible to make a dose-response curve up to 50% inhibition with bioactivated CB 77 and BDE 47. The toxic potencies of bioactivated persistent organic pollutants (POPs) should be taken into account to prevent serious underestimation of their hazard and risk.
Metabolic activation of polychlorinated biphenyls (PCBs) and polybrominated diphenyl-ethers (PBDEs) has attracted scientific and societal interest and concern. These persistent organic pollutants (POPs) are accumulated by organisms and magnified through the food chain (Kelly et al., 2008) . Upon uptake, PCBs and PBDEs can be transformed by phase I metabolic enzymes into hydroxylated compounds (Marsh et al., 2006; Morse et al., 1995) . These metabolites can cause direct effects on the thyroid hormone homeostasis (Freitas et al., 2011; Gutleb et al., 2010; Meerts et al., 2002) , interact with the estrogenic receptor (Hamers et al., 2006; Meerts et al., 2001) , increase steroidogenic gene expression (Song et al., 2008) , and might be the underlying cause for observed neurological effects of PBDEs (Dingemans et al., 2011) .
Several of the effects of hydroxylated PCB and PBDE metabolites (OH-PCB/PBDEs) are driven by their competition with 3,3´,5,5´-tetraiodo-L-thyronine (thyroxine, T 4 ) to bind the plasma transport proteins, their subsequent accumulation in tissues, and their specific transport over selective barriers (Meerts et al., 2002; Morse et al., 1993) . OH-PCBs and OH-PBDEs have a structural similarity with the thyroid hormones T 4 and 3,3´,5-triiodo-L-thyroxine (T 3 ). Therefore, they bind with high affinity to specific transport proteins such as transthyretin (TTR) and thyroxin-binding globulin (TBG) (Lans et al., 1994; Marchesini et al., 2006; Meerts et al., 2000) . As a result of this binding, OH-POP levels have been shown to be similar or up to 30 times higher in plasma than the respective parent compounds in mammals (up to 2.8 μg/g wet weight) (Gebbink et al., 2008) and as high as the parent compounds in humans (up to 22 ng/g wet weight) (Sjödin et al., 2000) . This mechanism is then the basis for the selective retention of OH-PCB/PBDEs in various tissues and their transport through selective barriers to the brain or the fetus (Meerts et al., 2002; Morse et al., 1993) . Given the high plasma levels and the toxicological relevance of the metabolite effects, it is very important to quantify the toxic potencies of these OH-POPs in order to take them into account for toxicological hazard and risk assessment of PCBs and PBDEs.
Mainly three in vitro methods to measure the potency of competitors to displace T 4 from TTR and TBG have been reported. The radio-ligand binding assay (RBA) uses radioactive T 4 (T 4 * ) in equilibrium with T 4 , TTR, and the competitor at 4°C. The amount of unbound T 4 * is a measure of the competitor's potency (Lans et al., 1993) . The plasmon resonance-based biosensor assay (Biacore) uses immobilized T 4 , which interacts with a mobile phase containing TTR or TBG and the competitor. The availability of free TTR for binding the immobilized T 4 is a measure of the competitor's potency (Marchesini et al., 2006) . Finally, the fluorescence displacement method is based on the measurement of the fluorescence emitted by a fluorophore when bound to proteins such as TTR, TGB, or albumin. A competitor will displace the fluorophore from its position in the protein, thereby reducing the fluorescence as a measure of the compound's potency to displace T 4 .
These methods have all been successfully used to measure the competitive binding of pure substances, but efforts to measure the metabolite potency of biologically metabolized PCBs and PBDEs have encountered several problems. The analysis of bioactivated extracts using in vitro biotransformation techniques with microsomal fractions has been hampered by the low biotransformation efficiencies, presence of toxic parent compound concentrations in the extracts, and the presence of interfering matrix components coextracted from the metabolizing system (Hamers et al., 2008; Meerts et al., 2000; Schriks et al., 2006) . In contrast to the parent compounds, the OH-metabolites do not endure destructive clean-up steps, and their physical/chemical qualities make it difficult to separate them from potentially interfering substances in the extract. Recent attempts to remove the interfering matrix components from extracted tissues by exhaustive clean-up procedures and 30 to 100 times sample dilution have been reported, but these could still not prevent interference with the analysis by matrix compounds coextracted from plasma and muscle samples (Simon et al., 2010 (Simon et al., , 2011 .
Well-known compounds that interfere with T 4 binding to TTR are the free fatty acids. The fact that human plasma free fatty acids present in micromolar concentrations can directly inhibit T 4 binding to TTR was the reason for the decision not to use T 4 -TTR binding assays to determine the plasma T 4 levels in humans in the clinical setting (Shaw et al., 1976) . In addition, the free T 4 * used in the RBA is prevented from binding to TTR at higher fatty acid concentrations, and it is transported through the column causing an overestimation of the competitive potency (Simon et al., 2010; Weiss et al., 2009) . However, the identity concentration and T 4 -TTR binding potency of the interfering coextractants from bioactivated extracts are not yet known. This information is required in order to solve the problem of disturbing coextractants and thus enable to study the toxic potencies of the ubiquitous OH-metabolite from POPs, such as PCBs and PBDEs.
In addition, a method to be able to quantify the TTR binding potency of the OH-metabolites without the use of radioactivity and expensive equipment and/or in relatively great quantities such in cuvettes is desired. Therefore, this study aims to (1) identify and quantify the concentration of coextractants in microsomal extracts, (2) quantify the potency of coextractants to inhibit the T 4 -TTR competitive binding assay, (3) develop a method to selectively extract metabolites and eliminate disturbing coextractants, and (4) apply the newly developed method to analyze the potency of bioactivated extracts from CB 77 and BDE 47, which are used as representative model compounds. To support these objectives, we developed (5) a selective chromatographic method to analyze silylated derivatives from CB 77 and BDE 47 OH-metabolites and coextractants and (6) a T 4 -TTR competitive fluorescence displacement method in a 96-well plate setup according to a published method for cuvettes .
MATERIALS AND METHODS
Standards and reagents. The model compounds 3,3´,4,4´-tetrachlorobiphenyl (CB 77, 99.0%) and 2,2´,4,4´-tetrabromodiphenylether (BDE 47, 98.8%) were purchased from Sigma-Aldrich Co. (Steinheim, Germany) and Chiron AS (Trondheim, Norway), respectively. CB 77 metabolites including 2-OH-3,3´,4,4´-CB (2-OH CB 77) and 5-OH-3,3´,4,4´-CB (5-OH CB 77) were previously synthesized in our laboratory (Lans et al., 1993) , whereas 4´-OH-3,3´,4,5´-CB 79 (4´-OH CB 79) was purchased from LGC Promochem (Middlesex, U.K.). BDE 47 metabolites including 2´-OH-2,3´,4,5´-BDE (2´-OH BDE 66) and 6-OH-2,2´,4,4´-BDE (6-OH BDE 47) were provided by Åke Berkgman and were synthesized as previously described (Marsh et al., 2003) . 6´-OH-2,2´,4,5´(6´-OH BDE 49), 5-OH-2,2´,4,4´-BDE (5-OH BDE 47), 4-OH-2,2´,3,4´-BDE (4-OH BDE 42), 4´-OH-2,2´,4,5´-BDE (4´-OH BDE 49), and 3-OH-2,2´,4,4´-BDE (3-OH BDE 47) were purchased from Accustandar (New Haven, CT). The internal standard for chromatographic analysis 2,2´,3,3´,4,4´,5,5´,6,6´ decaCB (CB 209) was obtained from Riedel-de Haën (Seelze, Germany). Fatty acids including dodecanoic acid, myristic acid, and palmitic acid were purchased from Supelco (Bellefonte, PA), whereas linoleic acid, oleic acid, stearic acid, and arachidonic acid were purchased from Sigma-Aldrich Co. (Steinheim, Germany). Cholesterol was purchased from Vel (Leuven, Belgium) . N,O-bis(trimethylsilyl)-trifluoroacetamidetrimethylchlorosilane (BSTFA-TCMS) (9:1) solution and lipid removal agent (LRA) were purchased from Supelco (Bellefonte, PA). Hexane (dioxin analysis grade) and all other solvents (chromatographic grade) were purchased from Biosolve BV (Valkenswaard, The Netherlands) or from Sigma-Aldrich Co. (Steinheim, Germany). Stock solutions were prepared in dimethyl sulfoxide (DMSO) for bioassays, in iso-octane for storage, and in hexane (dioxin analysis grade) for chromatographic analysis. β-Nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate (NADPH), 3,3´,5,5´-tetraiodo-L-thyroxin (T 4 ), prealbumin from human plasma (TTR), and the fluorescent probe 8-anilino-1-naphthalenesulfonic acid ammonium salt (ANSA) were purchased from Sigma-Aldrich Co. Concentrations of T 4 and ANSA were routinely determined by UV-visible spectrometry with a Beckman Coulter DU 800 spectrophotometer. Extinction coefficients were 6180 M −1 cm −1 at 325 nm in buffer phosphate and NaOH at pH 11 for T 4 and 6300 M −1 cm −1 at 350 nm in buffer phosphate at pH 7.5 for ANSA (Cao et al., 2010) . All extraction and storage materials were exclusively made of borosilicate glass prewashed with hexane, and polytetrafluoroethylene screw cap vials were used when required.
Microsomal incubations.
In vitro bioactivation of PCBs and PBDEs has been previously described (Murk et al., 1994) and was applied with few modifications given below. Compounds were metabolized using liver S9 fraction from β-naphthoflavone and phenobarbital-treated Sprague Dawley rats obtained from Xenotech (Lenexa, Kansas). Incubations were performed in a borosilicate TRANSTHYRETIN BINDING OF BIOACTIVATED THYROID HORMONE DISRUPTORS glass tube in 1 ml phosphate buffer (PB, 100mM, pH 7.5), S9 fraction (1 mg protein/ml), and parent compound (10μM in 1% DMSO). After 5 min preincubation in a shaking water bath at 37°C, the reaction was initiated with the addition of 100 μl of 10mM NADPH in PB. Additional 100 μl of 10mM NADPH was added every 20 min during the incubation period. Metabolism was stopped after 90 min (Harju et al., 2007) by denaturation of microsomal proteins with 700 μl of ice-cold methanol (negative controls at t = 0). Some incubations were spiked with 4-OH CB 79, 2-OH BDE 66, and 6-OH BDE 47 (2μM) to quantify extraction recovery and to study the potential production of dihydroxy metabolites. Coextractants and metabolites were analyzed as silylated derivatives by Gas chromatography/mass spectrometry (GC/MS) as described further below.
Metabolite extraction methods. To qualify and quantify the amount of coextractants from the incubation mixture, S9 control incubations were spiked with 2 nmol 4-OH CB 79/mg-eq protein in DMSO and extracted using four methods published in literature for POP OH-metabolites. The first method (M1) was a liquid-liquid extraction from the incubation mixture with diisopropyl ether (DIPE), and acidification was performed only during the third extraction step (Murk et al., 1994) . The second method (M2) was a modification of the previous one with a centrifugation step before extraction (Hamers et al., 2008) . Except for the use of methyl tert-butylether (MTBE) instead of DIPE, M1 and M2 were performed as published. The third and the fourth extraction methods (M3 and M4) correspond to the crude and the phenolic organohalogen extraction methods published by Hovander et al. (2000) . When required, the protocols were downsized to fit the incubation volume. All extracts were evaporated under gentle N 2 flow and redissolved in 1 ml of hexane for GC analysis or transferred into 50 μl of MeOH for bioanalysis.
Chromatographic analysis. We developed a selective ion chromatographic method to analyze coextractants and metabolites in one run. GC/MS was performed on a HP 6890 coupled to an Agilent 5973 mass spectrometer all from Agilent Technologies. Helium 99.99% was used as a carrier gas at a constant flow of 1.2 ml/min; the inlet temperature was set at 250°C, whereas the transfer line was kept at 280°C. Injection volume was 1 μl. Separation was achieved through an Rxi-5ms capillary column, 30 m × 0.25 m, 0.25 μm film thickness (Restek). The temperature program was set to 80°C for 2 min, raised at 30°C min −1 to 220°C, which was held for 15 min, and then raised at 15°C min −1 to 300°C and held for 3 min, for a total of 30 min. Electron ionization (EI) was used at an ion source temperature of 230°C and an electron energy of 70 eV. Chromatographic data were recorded and analyzed with Chemstation (Agilent Technologies). High-sensitivity electron impact (EI) mass spectra from silylated metabolites were obtained with GC/MS-MS (Supplementary data 1).
Extracts, POP OH-metabolites, selected fatty acids, and cholesterol were silylated by mixing 20 μl of compound standard solution or extract in hexane with 40 μl of BSTFA-TCMS (9:1), which contained 1 μg/ml of CB 209 as internal standard (IS), in GC vials. They were heated on a plate at 70°C for 30 min and then transferred into inserts for GC analysis. Identification of coextractants and produced metabolites was achieved through analysis of fragmentation patterns and retention time from their trimethylsilyl derivatives (Table 1) and their comparison with standards. Quantification was done using a multicompound external calibration, which was run with every analysis (Fig. 1A) . The limit of detection of the OH-metabolites was calculated from the blank microsomal extract base line and subsequently confirmed by the analysis of three extracts of blank microsomal incubations spiked with OH-metabolites at the limit of detection level (Table 1) .
ANSA displacement assay. The basic principle of the fluorescence displacement assay is the shift in fluorescence peak of the ANSA fluorescence probe, after binding to transport proteins such as human serum albumin, TTR, and TBG. The shift in the fluorescence peak is from 515 to 465 nm with a large increase in quantum yield. Fluorescent displacement of ANSA bound to TTR by competitors has been published using spectrometric detection with cuvettes (Cao et al., 2010 (Cao et al., , 2011 . We developed a method in a 96-well plate setup for TTR binding according to the same principle, which was optimized for a variety of method variables including plate type, measurement angle, emission filter, and sensitivity settings. The equilibrium between bound and unbound ligand is very sensitive for incubation conditions, and therefore, incubation volume, time, temperature, reactants, and solvent concentrations were optimized and standardized (Supplementary data 2). Subsequently, the ANSA-TTR fluorescence coefficient was obtained after titration of increasing ANSA concentrations [ANSA] into a 0.5μM TTR solution in PB. From the linear part of the curve between [ANSA] and the fluorescence intensity (F λ ), the fluorescence coefficient (B) was obtained (Möller and Denicola, 2002) TTR binding experiments. Dose-related binding of T 4 , coextractants, and metabolite standards to TTR was assessed in the ANSA-TTR displacement assay. Standard solutions in MeOH (2.5% final concentration) were mixed in a round-bottom 96-well plate (Greiner Bio-One) with 0.6μM ANSA and 0.5μM TTR in 100 μl PB at pH 7.5. After 2 h of incubation at 4°C, the plate was gently shaken for 10 s and measured in a Biotech Synergy 2 plate reader (Winooski, VT). ANSA fluorescence was excited using a 380 ± 20 nm filter, and the emission was measured with a 475 ± 20 nm filter. Negative controls without TTR, ANSA-TTR positive controls, and T 4 0, 100, and 600nM displacement controls were included on every plate. Variation coefficients for repeatability and reproducibility were determined using replicates on separate plates and separate experiments, respectively. The detection limit was set at thrice the SD of the control without TTR. Data were expressed as fluorescence relative to the ANSA-TTR maximal fluorescence (positive control) unless otherwise stated. The 20 or 50% inhibition potency (IC 20 or 50 ) for the competitors was obtained after fitting the dose-related decrease in relative fluorescence units (RFU) into a dose-response model using SigmaPlot 2001 (SPSS Inc.). Subsequently, the IC 50 was used to calculate the competitors' dissociation constant (K dI ) (Yung and Prusoff, 1973) and then its inverse to render their binding (association) constant K bI . These inhibition parameters were compared with the potency of T 4 tested under similar conditions. New method for low-fat metabolite extraction. A new method for low-fat metabolite extraction (M5) was developed based on M3 and M4 (Hovander et al., 2000) , with modifications based on various experiments performed during this study. Preliminary T 4 -TTR competition experiments with microsomal extracts performed with the Biacore showed that selected fatty acids and cholesterol bind to the dextran-coated chip surface (data not shown). To selectively retain fatty acids, the incubation mixture (1 ml) was mixed with 50 μl of a 10% dextran solution from Leuconostoc spp. in phosphate buffer in addition to 50 μl of 6M HCl for acidification. This mixture makes the coextractants precipitate, and the subsequent centrifugation (3 min, 1500 g, 4°C) further compacted the flocks. The incubation mixture including the flocs was extracted twice with 1 ml of hexane:MTBE (1:1, vol/vol). After vigorous vortexing and centrifugation (1 min, 1500 g), the organic phases were transferred into a second test tube containing 1 ml of an aqueous KCl solution (1%, wt/wt). After gentle mixing and centrifugation (30 s, 1000 g), the organic phase was transferred to a clean test tube, and the KCl solution was reextracted with 1 ml of hexane:MTBE. The combined organic phases were reduced to a 50-μl extract (20 mg-eq protein/ ml) under gentle N 2 flow.
Fatty acids and other higher molecular weight lipids were separated from the metabolites with a LRA minicolumn made with 0.8 g of LRA and 0.3 g of Na 2 SO 4 packed on top of a glass wool plug in a Pasteur pipette. The LRA minicolumn was washed with 2 ml of hexane:MTBE (1:1) before the 50-μl extract was transferred to the minicolumn. The extract tube was rinsed twice with 150 μl of hexane:MTBE (1:1), which was transferred into the LRA column as well. This eluate from the LRA column (350 μl from the 50-μl extract and 2 × 150 μl rinsing) was discarded. Then the column was further eluted with 1600 μl of the same solvent, which was collected into a prewashed test tube where it was dried 96 MONTAÑO ET AL. under gentle N 2 flow, and redissolved in either 1-ml hexane (1 mg-eq protein/ ml) for chemical analysis or 50-μl MeOH (20 mg-eq protein/ml) for bioanalysis.
TTR binding of CB 77 and BDE 47 metabolic extracts. The microsomal blank, OH-POP spiked incubations, and incubations with CB 77 and BDE 47 were extracted with the optimized M5 method. Metabolites were identified and quantified after silylation using GC/MS as described above. Extracts in MeOH were serially diluted up to 64 times and used to measure their ANSA-TTR fluorescence displacement potency relative to that of T 4 based on the linear part of the curve. The bioassay T 4 -Eq was compared with the T 4 equivalents calculated from the chemically analyzed metabolite concentrations multiplied by the T 4 equivalent factors from our own study or from literature (Hamers et al., 2008) . In the absence of complete dose-response curves, significant differences with extraction blanks and negative incubations were assessed with ANOVA followed by a LSD post hoc comparison (SPSS Inc.).
RESULTS

Identification and Quantification of Coextractants
After extraction of blank microsomal S9 fraction incubations with four published methods, the chromatographic profiles of the extracts included various SFA, NSFA, and cholesterol (Fig. 1B) . For identification, the relative retention times and mass spectrometric characteristics were compared with standards when available (Table 1) .
Per milligram original microsomal protein (mg-eq protein), the four methods extracted 12-24 nmol SFA, 3.6-8.2 nmol NSFA, and 0.1-26 nmol cholesterol. The M1 produced the highest quantity of coextractants, whereas the M2 limited the amount of SFA and NSFA extracted to almost 50% compared with M1 (Table 2 ). M3 had slightly lower quantities of SFA, NSFA, and cholesterol compared with the extract obtained with M1. Furthermore, the phenolic extract obtained with M4 contained only detectable quantities of cholesterol, but the extraction roughly doubled the amount of SFAs and NSFAs, particularly that of arachidonic acid. Now that the coextractants have been identified and quantified, their relevance in disruption of the competitive TTR binding assay will be analyzed.
ANSA Fluorescence Displacement Assay
The ANSA fluorescence displacement assay was optimized for ANSA-TTR binding. The intensity of ANSA bound to TTR was optimal when performed in a round-bottom 96-well plate and the fluorescence measured from the bottom, with a 380 ± 20 nm excitation filter and a 475 ± 20 emission filter. The optimal ANSA concentration was 0.6µM and TTR 0.5µM. Equilibrium conditions were achieved after 2 h of incubation b Limit of detection calculated from a blank microsomal extract base line and confirmed by extracts from spiked incubations at the limit of detection level. As the total protein was 1 mg/ml the units nmol/mg protein are equivalent to micromole. ANSA in the absence of TTR gives background fluorescence, and neither MeOH nor DMSO (<20%) interfered with this background fluorescence. However, the fluorescence of ANSA in the presence of TTR was significantly reduced by DMSO and by MeOH above 2.5% (Fig. 2) . From the titration of ANSA into 0.5µM TTR, the ANSA K b was calculated to be 1.06 ± 0.13 × 10 6 M −1 (Fig. 3) . There was indeed a significant interaction between the effect of 2.5% MeOH and the effect of ANSA concentration (ANOVA, p < 0.05); MeOH increased fluorescence at high ANSA concentrations (> 6μM). However, the overall effect of 2.5% MeOH on the ANSA titration into TTR was not significant (p < 0.01) and particularly not at lower ANSA concentrations (Fig. 3) . ANSA K b in the presence of 2.5% MeOH was 0.97 ± 0.08 × 10 6 M −1 , which was in consequence not significantly different from the one without MeOH (p < 0.01). Therefore, 2.5% was chosen as maximal solvent concentration for further ANSA-TTR experiments.
Using a dose-response design, T 4 reduced the fluorescence signal from 0.6μM ANSA plus 0.5μM TTR in a dose-dependent manner with an IC 20 of 80 ± 16nM, an IC 50 of 265 ± 8.2nM (Fig. 4A ) and a limit of detection of 60 ± 12nM T 4 . The T 4 binding constant was 6.0 ± 0.2 × 10 6 M −1 (Table 3 ). The repeatability was typically 5%, and the reproducibility was 9% when the same lot of TTR was used and was up to 15% when experiments were performed with different TTR lots. Figure 4B shows the full ANSA-TTR displacement curves for the four OH-CB 77 and OH-BDE 47 metabolite standards. Their relative potencies compared with that of T 4 are given in Table 3 .
FIG. 1.
Chromatogram from silylated derivatives of a standard mixture (A) and of a S9 microsomal blank extracted with M1(B). Silylation internal standard (IS) was CB 209; surrogate standards were 4-OH CB 79, 2-OH BDE 66, and 6-OH BDE 47. Fatty acids were named with their common name. 
TTR Competitive Binding of Coextractants
The S9 coextractants identified in the extracts of the four extraction methods all displaced ANSA from TTR with the exception of cholesterol and stearic acid (Figs. 5A and B) . The SFAs significantly displaced ANSA fluorescence from 1μM on, with dodecanoic acid and myristic acid fully displacing ANSA at 30μM, whereas palmitic acid only partially displaced it (Fig. 5A ). NSFAs had a significant effect already from 0.3μM and completely displaced ANSA fluorescence at 30μM (Fig. 4B) . Inhibition potencies of fatty acids were 5 to 30 times lower than that of T 4 and 2-10 times lower than the OH-metabolites. The fatty acid TTR binding constants are one order of magnitude lower compared with T 4 (Table 3) . Given the TTR binding potency of the SFAs and NSFAs and their concentrations in the extract, it is important to further reduce the coextracted levels in the metabolic extract.
Reduction of Coextractants in the Metabolic Extract
A new extraction method M5 was developed to limit the coextractant concentrations and their effects in the TTR competition assay. The new method included protein denaturation and lipid flocculation with the addition of 10% dextran at pH < 2, liquid-liquid extraction, and a LRA minicolumn. The addition of 10% dextran at pH < 2 already reduced SFAs 50% compared with M3 to 6 nmol/mg eq protein and NSFAs to 2 nmol/mg eq protein. The LRA minicolumn improved this removal further. Figure 6 shows the elution profile of coextractants and OH-POP metabolites through the LRA minicolumn. The metabolites eluted from 0.4 to 2 ml (Fig. 6) . SFA eluted constantly from the column, whereas NSFA and particularly oleic and linoleic acids eluted mainly between 1.2 and 2.4 ml. Arachidonic acid did not elute before 4 ml (Fig. 6 ) and therefore could be reduced to 0.12 nmol/mg-eq protein, which corresponds to a reduction of more than 21 times compared with M1 (Table 2) .
With M5, 5 to 10 times less SFAs and 7 to 20 less NSFAs were extracted than with any of the other methods tested (Table 2) . Cholesterol concentration was five times lower than with M1, three times lower than with M3, but considerably higher compared with M4 (Table 2) .
A 0.5 mg-eq protein/ml microsomal blank extract prepared with M5 and spiked with 3 nmol T 4 /mg-eq protein produced a displacement curve that was not significantly different from that obtained spiking MeOH with a similar amount of T 4 (Fig. 7) . However, the undiluted microsomal extract significantly competed with ANSA-TTR binding above 0.25 mg-eq protein/ml with a competitive potency of 0.3 nmol T 4 -Eq/mg-eq protein (Fig. 8) . Despite the interference at higher extract concentrations, spiked S9 microsomal incubations were extracted and successfully quantified. An extract spiked with 2 nmol T 4 -Eq of 4-OH CB 77/mg-eq protein produced 2.3 T 4 -Eq/mg-eq protein, and the extract spiked with 0.3 T 4 -Eq OH-metabolite mixture/mg-eq protein resulted in a quantified potency of 0.5 T 4 -Eq/mg-eq protein.
TTR Competitive Binding by Extracts With Bioactivated CB 77 and BDE 47
Finally S9 microsomes were incubated during 90 min with 10μM CB 77 or BDE 47 and extracted with the newly developed M5 method. The extracts were chemically analyzed and tested in the ANSA TTR displacement assay (Table 4) . MS details of silylated metabolites are presented and discussed in Supplementary data 1. In vitro metabolism of CB 77 produced mainly 4-OH CB 79, which accounted for 68% of the total metabolite fraction, followed by 20% of 5-OH CB 77 and 16% of 2-OH CB 77. The most abundant metabolite from BDE 47 was 4´-OH BDE 49 with 48% of the total followed by 3-OH BDE 47 and 5-OH BDE 47, which accounted for 25% each, and trace amounts of 2´-OH BDE 66 and 4-OH BDE 47. Considering the final concentration of metabolites, the calculated metabolic rates were 33 and 6 pmol mg protein −1 min −1
for CB 77 and BDE 47, respectively. Metabolic extracts from both CB 77 and BDE 47 reduced ANSA fluorescence in a dosedependent manner, but the differences with the dilution range of the incubation blank were small and not always statistically significant (Fig. 9) . Incubations stopped at t = 0 were not significantly different from incubation blanks (solvent controls; data not shown). At the T 4 IC 20 level, the bioassay T 4 -Eq was 0.3 nmol T 4 -Eq/mg-eq protein for the CB 77 metabolic extract and 0.6 nmol T 4 -Eq/mg-eq protein for the BDE 47 bioactivated extract.
DISCUSSION
A method was developed to reduce the concentrations of the coextractants from bioactivated mixtures of PCB and BDE that disturb the TTR binding assays. With an optimized method for silylation, the identities and concentrations of extracted fatty acids and OH-metabolites were obtained, and their TTR binding potencies were quantified in a downscaled, nonradioactive TTR binding ANSA assay in a 96-well plate. The greatly improved removal of especially fatty acids from the microsomal extracts allows quantification of the TTR binding potency of the in vitro produced metabolites at the IC 20 level.
Optimization of the S9 Extraction Method
The published metabolite extraction methods also are efficient in extracting lipids including free fatty acids, cholesterol, and acidic phospholipids, which are neutral at low pH. The observed fatty acid composition was very similar to that reported for human liver microsomes and trout S9 liver fractions, whereas the sum of fatty acids and cholesterol was only 4-10% of the total reported lipid content (Belina et al., 1975; Escher and Fenner, 2011; Waskell et al., 1982) . Therefore, M1, M2, and M3 are already efficient at limiting the coextracted fatty acid content. Nevertheless, fatty acids can also be produced by hydrolysis of coextracted phospholipids. This was observed in the increase of NSFAs and particularly the arachidonic acid content in the M4 extract (Table 2) . Neutral phospholipids such as phosphatidylserine have a higher arachidonic acid concentration (Waskell et al., 1982) ; it was likely hydrolyzed under the highly basic conditions during the final extraction step in M4 increasing the coextracted free fatty acid. The addition of dextran in M5   FIG. 6 . Elution profile of a standard mixture through an 80-mg LRA minicolumn. Concentrations of OH-metabolites, cholesterol, SFA, and NSFA were obtained after GC/MS analysis of eluates. In the M5, the first 0.4 ml is discarded as is everything after 2 ml. Data represent average ± SD from two independent experiments each with four separate columns. TRANSTHYRETIN BINDING OF BIOACTIVATED THYROID HORMONE DISRUPTORS partially reversed the transfer equilibrium of free fatty acids to the organic phase by their retention in the flock; the LRA minicolumn selectively retained heavier NSFA. And finally, lipolytic conditions were avoided in the newly developed method.
Interaction of Coextractants With TTR Binding
The inhibitory effect of fatty acids and particularly NSFA on the competitive protein-binding assay has long been known by clinicians who tried to develop a method to determine the free T 4 in plasma by testing its binding potency to transport proteins. The most potent inhibitors of T 4 binding to TBG and TTR are short-chain SFA and long-chain NSFA (Shaw et al., 1976) . We confirmed this with our downscaled ANSA displacement assay (Table 3) . The fatty acids' binding constants obtained here were similar to reported values (Tabachnick and Korcek, 1986) , but their IC 50 were lower than previously reported values (Shaw et al., 1976) . These differences are commonly due to variation in protein source and purity . Although triglycerides have been found not to interfere with the assay (Shaw et al., 1976; Simon et al., 2010) , the influence from the small coextracted amount of phospholipids is uncertain. Under M5 conditions, however, the LRA minicolumn is expected to completely retain both triglycerides and phospholipids.
It was not known whether the fatty acid disruption of the T 4 -TTR binding is the result of their direct interaction with T 4 (Shaw et al., 1976; Simon et al., 2010) or due to their interaction with the TTR binding sites (Tabachnick and Korcek, 1986) . As the ANSA-TTR fluorescence displacement assay presented here does not require the presence of T 4 and FA did not interfere with ANSA fluorescence, it is suggested that the observed inhibitory effect is caused by interaction of the FA with the TTR. Considering reported results with the TTR-T 4 RBA and results presented here, it is reasonable to suggest that observed assay disturbances are a combined effect of two mechanisms: a direct interaction of FA with T 4 at high fatty acid concentrations (observed in the RBA assay) and TTR competitive inhibition by FA at lower concentrations (observed here). This would explain observed U shapes with muscle extracts in the RBA competitive binding assay (Simon et al., 2010) . In summary, a method that does not include T 4 for the competitive binding measurements, like the ANSA-TTR fluorescence displacement assay, is one step further reducing the disturbing action of coextractants.
The obtained ANSA-TTR binding constant (1.06 × 10 6 M −1 ) in the 96-well ANSA assay was in agreement with previously published values between 1 and 36 × 10 6 M −1 (Cao et al., 2010; Cheng et al., 1977; . The calculated T 4 binding constant (6.0 × 10 6 M −1 ) was one order of magnitude lower compared with published data (10 × 10 7 M −1 ) for the ANSA-TTR assay with cuvettes (Cao et al., 2010; . Lans et al. (1993) ) in the RBA. This difference in relative binding affinity was reflected in the obtained T 4 IC 50 , which was 3 to 10 times higher in the ANSA assay than previously reported values (Cao et al., 2010; Lans et al., 1993; Marchesini et al., 2008; Meerts et al., 2000) . These differences could also be attributed to variations in protein sources. However, despite the lower sensitivity obtained in the 96-well plate ANSA displacement assay, the T 4 -relative potencies for OH-POP metabolites were in agreement with literature (Cao et al., 2010; Lans et al., 1993; Marchesini et al., 2008; Meerts et al., 2000) . In addition to the advantage of excluding potential interaction of FA with T 4 from TTR competitive binding incubations, the ANSA displacement assay has several other advantages compared with previously used methods (Lans et al., 1993; Marchesini et al., 2006) : a a Calculated T 4 equivalents from the chemically analyzed metabolite concentrations multiplied by the T4 equivalent factors from our own study or from literature (Hamers et al., 2008) . The bold values here merely serve to mark the sum of congeners.
FIG. 9.
Effect of CB 77 and SBDE 47 metabolic incubation extracts. Microsomal incubation blanks with DMSO (circles), with CB 77 (triangles), and with BDE 47 (squares) were extracted according to the M5 method; the 0.5 mg-eq protein/ml extracts were diluted up to 68 times and titrated into a solution of 0.6μM ANSA and 0.5μM TTR. Data represent the average of fluorescence intensity relative to the maximum of an ANSA-TTR solution ± SD of at least two separate extracts in triplicate. * indicates significant differences when comparing with incubation blank in DMSO (p < 0.05) after an ANOVA with LSD pos hoc comparison.
(1) It does not require radioactive materials, (2) the cumbersome and sometimes not reproducible immobilization of hormone to the biosensor chip is not needed, and (3) expensive biosensor equipment is not required. The downscaling of the ANSA fluorescence displacement method into a 96-well plate format brings the additional advantages: (1) reduction of amounts of chemicals needed, (2) considerable reduction in analysis time, and (3) possibility for high throughput.
Presence of Interfering Coextractants
A typical microsomal incubation mixture (1 mg protein in 1 ml) is mostly concentrated in 50 µl of MeOH or DMSO (so the coextractants are 20 times concentrated) followed by 40-times dilution in the TTR competitive assay solution. Thus, the final dilution factor usually is 2. Under these conditions, an undiluted extract obtained with M1 would have a concentration in plate of 12μM SFA and 3.3μM NSFA (Table 2) , which is well above their IC 50 s in the ANSA displacement assay (Table 3 ). The newly developed method reduced the amount of coextractants by 10 times compared with M1. An extract obtained with the modified method (M5) and finally diluted twice as mentioned above will contain less than 2.0μM SFA and 0.26μM NSFA, which are concentrations below the IC 50 for these compounds in the ANSA displacement method (Tables 2 and 3) . When the extract is tested "undiluted," some interference with the analysis is to be expected. As can be seen from Figure 8 , the blank microsomal extract will reduce ANSA binding at concentrations above 0.25 mg-eq protein/ml. This means that an extract diluted four times will have a FA below their competitive concentration, thus enabling an undisturbed analysis. This was corroborated by the results of Figure 7 where the ANSA displacement by T 4 in microsomal extract, prepared according to M5, was equal to the one in MeOH. This performance in a microsomal extract in a TTR competition assay is a considerable improvement compared with previously published results with fish and plasma, in which larger dilution regimes and cumbersome clean-up procedures were used (Simon et al., 2010 (Simon et al., , 2011 .
The metabolic profile and metabolic rates of CB 77 were in accordance with published results (Murk et al., 1996) , except that 6-OH-CB 77 was not detectable (Table 4) . Similarly, the obtained results agreed with proportions and metabolic rates published for BDE 47 (Hamers et al., 2008; Harju et al., 2007) . Metabolic extracts from CB 77 and BDE 47 reduced ANSA fluorescence significantly above 0.12 mg-eq protein/ml. However, due to the effects of the coextractants at concentrations above 0.25 mg-eq pr/ml it is not possible to prepare a full dose-response curve with the amount of metabolites produced under the chosen conditions. Therefore, quantification has to be performed at a concentration around or below the IC 50 for PCB and PBDE OH-metabolites (Table 4 ). The calculated bioassay T 4 -Eq from the bioactivated CB 77 and BDE 47 was higher in comparison with the chemically obtained values (Table 4 ). An effect often seen with bioassays as also OH-metabolites present in levels below the limit of chemical detection will be contributing to the response in the bioanalysis.
CONCLUSIONS
SFA and, particularly, NSFA were identified along with cholesterol as the major coextractants upon OH-PCB and OH-BDE extraction from a PCB 77 and BDE 47 metabolic incubation with S9 liver fraction. The observed effect from the metabolic extracts in the ANSA fluorescence displacement assay is mainly due to the coextracted free fatty acids. A method to strongly reduce the coextraction of matrix components by including fat flocculation, liquid-liquid extraction, and a LRA minicolumn was developed. The extract obtained was used in the downscaled ANSA-TTR competitive fluorescence displacement assay to quantify the T 4 equivalents from samples spiked with OH-metabolites. GC-MS analysis of silylated derivatives was suitable to quantify the production of T 4 -like OH-metabolites from the model POP compounds. With bioactivated CB 77 and BDE 47 it is now possible to make a dose-response curve up to 50% ANSA-TTR inhibition. To make a full dose-response curve, the efficiency of the biotransformation should be further enhanced. The developed new extraction and clean-up method can also be applied to other biological matrices such as plasma or tissue extracts. 
